The building of an iPS cell stock for regenerative medicine involves the collection of cells from healthy donors with homozygous HLA (human leukocyte antigen). The aim of the stock is to hold iPS cells of guaranteed quality which can be supplied quickly to medical care institutions and research institutions in Japan and overseas when required. In April 2020, this project was transferred to the CiRA Foundation.

• CiRA Foundation｜iPS Cell Stock Project